Yaqi Li, Jing Xu, Xiang Hu, Yikuan Chen, Fangqi Liu, Yun Chen, Xiaoji Ma, Qiduo Dong, Lei Sun, Shaobo Mo, Long Zhang, Xingfeng He, Shanyou Tong, Huizi Wu, Wenhua Li, Sanjun Cai, Shida Zhu, Qi Pan, Junjie Peng
BACKGROUND: Approximately 60% of patients with CRLM experience relapse within 2 years after radical resection, previous studies have proven that repeat local treatment (LT) could prolong survival, however, it is difficult to seize the window for LT due to the lack of a high-sensitive surveillance method. In this study, we aim to examine the value of longitudinal circulating tumor DNA (ctDNA) in guiding adjuvant chemotherapy (ACT), optimizing clinical surveillance strategy, and thereby improving CRLM outcomes...
March 4, 2024: International Journal of Surgery